echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > National Medical Insurance Bureau: The "two-invoice system" will not be abolished for the time being

    National Medical Insurance Bureau: The "two-invoice system" will not be abolished for the time being

    • Last Update: 2022-10-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    A few days ago, the National Medical Insurance Bureau made it clear in the "Letter on the Reply to the Proposal No.
    04377 (Medical and Health No.
    414) of the Fifth Meeting of the 13th National Committee of the Chinese People's Political Consultative Conference" (hereinafter referred to as the reply letter) that the "two-invoice system" for the procurement of pharmaceutical consumables by medical institutions still plays an important role and is not suitable for cancellation
    at present.
    The "two-invoice system" means that the pharmaceutical manufacturer issues an invoice once to the circulation enterprise, and the circulation enterprise issues one invoice
    to the medical institution.
    In April 2016, the executive meeting of the State Council proposed to implement the "two-invoice system" reform, the main purpose of which is to control the chaos in the field of drug circulation, reduce the links of drug circulation, prevent money laundering and unhealthy trends, reduce inflated drug prices, strengthen drug supervision, and ensure the safety
    of patients' medication.
    In December of the same year, the former State Council Medical Reform Office and other eight departments jointly issued the "Implementation Opinions on the Implementation of the "Two-invoice System" in the Drug Procurement of Public Medical Institutions (Trial)", which clearly stated that the "two-invoice system"
    should be implemented in the drug procurement of public medical institutions.
    At the same time, it is specially proposed to "distribute drugs to particularly remote township (town) and village medical and health institutions, and allow drug circulation enterprises to issue another invoice for drug purchase and sale on the basis of the 'two-invoice system'" to ensure the supply of
    drugs at the grassroots level.
    The National Medical Insurance Bureau said in its reply letter that the "two-invoice system" played a role in regulating the circulation market, accelerating the integration and large-scale development of the circulation field, and was an important measure
    to control the chaos in the drug market at that time.
    Since 2018, the National Medical Insurance Bureau, together with relevant departments, has promoted centralized and quantitative procurement of drugs and reconstructed the order
    of drug circulation from the perspective of institutional mechanisms.
    Among the varieties covered by collective procurement, production and distribution enterprises take the initiative to simplify the circulation links and the number of invoices, effectively purifying the drug circulation channels
    .
    At present, the national level has organized and carried out 7 batches of centralized procurement of drugs, covering a total of 294 kinds of drugs, and local governments have also explored the collective procurement of some varieties, but a large number of varieties are still not covered
    .
    Therefore, the "two-vote system" still plays an important role
    .
    The National Medical Insurance Administration also said that the next step will be to work with relevant departments to promote the normalization and institutionalization of centralized procurement, accelerate the expansion of coverage, and gradually expand the coverage of
    centralized procurement products.
    At the same time, we will further improve the mechanism for forming drug prices on the Internet, establish and improve the market-led price discovery mechanism, guide market entities to actively optimize the distribution process, and squeeze out the inflated drug
    prices.
    At the same time, the relevant departments will consider
    the "two-vote system" together with relevant reforms.
    ={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
    appendChild(createElement('script')).
    src='http://bdimg.
    share.
    baidu.
    com/static/api/js/share.
    js?v=89860593.
    js?cdnversion='+~(-new Date()/36e5)];
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.